iCAD

iCAD, Inc. is a medical technology company, which engages in the provision of cancer detection and therapy solutions. It operates through the Cancer Detection and Cancer Therapy segments. The Cancer Detection segment includes image analysis and workflow products. The Cancer Therapy segment is composed of radiation therapy products. The company was founded in 1984 and is headquartered in Nashua, NH.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

iCAD implements strategic changes to drive profitability and growth

iCAD is strategically focusing on cost reduction, revenue diversification, and transitioning to a subscription model to drive profitability by 2024. Leveraging partnerships with Google and other organizations, the company aims to expand its market reach and enhance operational efficiency. Despite facing competition and market challenges, iCAD remains optimistic about its growth prospects.

iCAD reports Q1 revenue decline, eyes growth in AI healthcare

iCAD faced revenue decline in Q1 2023, with a focus on detection and therapy segments, while maintaining a strong gross profit margin.
The company's Xoft technology and partnership with Google Health present promising growth opportunities in the AI healthcare space.
Challenges include lower-than-expected Xoft business revenue, competition in AI software, and delays in partnership agreements.

iCAD reports Q2 revenue decline, eyes growth through strategic partnerships

iCAD's Q2 2023 Earnings Call showcased a revenue decline but highlighted progress in the detection segment and strategic partnerships. The company aims for recurring revenue through subscription deals and is focused on cost reductions and stability. Opportunities lie in expanding partnerships and securing growth with healthcare facilities globally.

iCAD reports improved operational metrics and strategic partnerships in Q3 '23

iCAD's Q3 '23 earnings call highlighted operational improvements, strategic partnerships, and a focus on growth initiatives. Despite a revenue decline and operating loss, the company has made progress in reducing EBITDA loss and cash burn. iCAD's financial position remains stable with sufficient resources for planned operations.

iCAD reports improved financials and strategic growth initiatives for 2024

iCAD's financial performance showed improvements in revenue, EBITDA loss, and operational efficiency, driven by strategic initiatives.
The company's focus on AI solutions, geographic expansion, and recurring revenue model positions it for future growth.
While facing challenges in market adoption and OpEx increases, iCAD has opportunities to capitalize on market growth and new product developments.

iCAD reports revenue growth and strategic expansion in Q1 2024

iCAD's Q1 2024 performance reflects positive momentum with revenue growth, improved profitability metrics, and strategic advancements
The company's focus on innovation, market expansion, and cost control positions them well for future growth and market leadership
While challenges like revenue seasonality and competitive pressures exist, iCAD's strengths in product development and global expansion offer opportunities for sustained growth
Overall, iCAD's Q1 2024 earnings call underscores a promising outlook with a strong foundation for continued success in the medical technology sector

iCAD reports 4% revenue growth, FDA clearance boosts cancer detection

iCAD's Q3 performance reflects growth in revenue and strategic partnerships, underpinned by AI technology.
While facing challenges in service revenue and net loss, the company's global expansion and product advancements signal resilience.
Opportunities lie in market expansion, innovation in breast cancer detection, and transitioning to a recurring revenue model.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

iCAD, Inc. is a global medical technology company, which engages in the provision of cancer detection and therapy solutions. It operates through the Cancer Detection and Cancer Therapy segments. The Cancer Detection segment includes image analysis and workflow products. The Cancer Therapy segment relates to radiation therapy products. The company was founded in 1984 and is headquartered in Nashua, NH.

iCAD’s cancer detection and therapy technologies to be exhibited together for the first time in the Middle East, including the world’s first commercial deep-learning digital breast tomosynthesis solution and a single-fraction therapy option for early-stage breast cancer iCAD’s cancer detection and therapy technologies to be exhibited together for the first time in the Middle East, including the world’s first commercial deep-learning digital breast tomosynthesis solution and a single-fraction therapy option for early-stage breast cancer

iCAD Showcases Technology for Cancer “Discovery to Recovery” including ProFound AI Platform and Xoft System at Arab Health 2020 in Dubai

World’s first and largest open AI Marketplace expands access to ProFound AI for U.S. radiologists, 80 percent of whom use Nuance’s radiology reporting system World’s first and largest open AI Marketplace expands access to ProFound AI for U.S. radiologists, 80 percent of whom use Nuance’s radiology reporting system

iCAD’s ProFound AI Joins Nuance AI Marketplace for Diagnostic Imaging

Company Unveils New Initiative, ProFound AI Powered by Panorama, which will Enable Breast Imaging Intelligence Technology to Correlate Findings Over Time Company Unveils New Initiative, ProFound AI Powered by Panorama, which will Enable Breast Imaging Intelligence Technology to Correlate Findings Over Time

iCAD to Showcase Leading Breast Health Solutions Suite Including Expanded ProFound AI™ Platform at RSNA Annual Meeting

ICAD, Inc. (ICAD) CEO Michael Klein on Q3 2019 Results - Earnings Call Transcript

Continued strong momentum for ProFound AI™ iCAD’s proprietary cancer detection AI technology

iCAD Reports Financial and Operating Results for the Third Quarter and Nine Months Ended September 30, 2019

iCAD to Showcase Entire ProFound AI Platform, including its Solutions for 2D Mammography and Digital Breast Tomosynthesis in Paris at Medical Conference iCAD to Showcase Entire ProFound AI Platform, including its Solutions for 2D Mammography and Digital Breast Tomosynthesis in Paris at Medical Conference

ProFound AI™ Platform Featured at Journées Francophones de Radiologie Congress in Paris

iCAD présentera la plateforme complète ProFound AI, comprenant ses solutions pour la mammographie 2D et pour la tomosynthèse mammaire numérique, lors du Congrès de Radiologie à Paris iCAD présentera la plateforme complète ProFound AI, comprenant ses solutions pour la mammographie 2D et pour la tomosynthèse mammaire numérique, lors du Congrès de Radiologie à Paris

La plateforme ProFound AI™ sera présentée lors du congrès des Journées francophones de Radiologie à Paris

Company to exhibit ProFound AI for 2D and 3D Mammography in Europe Company to exhibit ProFound AI for 2D and 3D Mammography in Europe

iCAD Showcases ProFound AI™ Platform at European Society of Breast Imaging Annual Scientific Meeting in Budapest

Enhanced x-ray source technology and full suite of Xoft eBx applicators to be showcased, including those for emerging applications in prostate, brain, and rectal cancers Enhanced x-ray source technology and full suite of Xoft eBx applicators to be showcased, including those for emerging applications in prostate, brain, and rectal cancers

iCAD Exhibiting New Updates and Enhanced Xoft Platform at ASTRO Including Single-Fraction IORT Solution for the Treatment of Early-Stage Breast Cancer

First and Only FDA-Cleared Digital Breast Tomosynthesis Software with Artificial Intelligence Clinically Proven to Enhance Breast Cancer Screening, Reduce False Positives and Slash Reading Time for Radiologists in Half First and Only FDA-Cleared Digital Breast Tomosynthesis Software with Artificial Intelligence Clinically Proven to Enhance Breast Cancer Screening, Reduce False Positives and Slash Reading Time for Radiologists in Half

iCAD’s ProFound AI Reader Study Published in Radiology: Artificial Intelligence

First and Only FDA-Cleared Artificial Intelligence Solution Supporting Breast Cancer Detection in 3D Tomosynthesis Recognized by Annual Awards Program First and Only FDA-Cleared Artificial Intelligence Solution Supporting Breast Cancer Detection in 3D Tomosynthesis Recognized by Annual Awards Program

iCAD’s ProFound AI Wins “Best New Radiology Solution” in 2019 MedTech Breakthrough Awards

iCAD's (ICAD) CEO Michael Klein on Q2 2019 Results - Earnings Call Transcript

iCAD's (ICAD) CEO Michael Klein on Q1 2019 Results - Earnings Call Transcript

iCAD, Inc. (ICAD) CEO Michael Klein on Q4 2018 Results - Earnings Call Transcript

News for iCAD Stock (ICAD)